Cargando…

Low apoA-I is associated with insulin resistance in patients with impaired glucose tolerance: a cross-sectional study

BACKGROUND: Low apolipoprotein A-I (apoA-I) is an independent risk factor for atherosclerotic cardiovascular diseases. Insulin resistance predicts the progression of abnormal glucose metabolism, which is the main cause of atherosclerotic cardiovascular disease. In this study, we assessed the potenti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Xiaomeng, Gao, Xia, Yao, Zhi, Xu, Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379622/ https://www.ncbi.nlm.nih.gov/pubmed/28372564 http://dx.doi.org/10.1186/s12944-017-0446-1

Ejemplares similares

Single injections of apoA-I acutely improve in vivo glucose tolerance in insulin-resistant mice
por: Stenkula, Karin G., et al.
Publicado: (2014)

Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent
por: Lebherz, Corinna, et al.
Publicado: (2007)

HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis
por: Chyu, Kuang-Yuh, et al.
Publicado: (2015)

Different Functional and Structural Characteristics between ApoA-I and ApoA-4 in Lipid-Free and Reconstituted HDL State: ApoA-4 Showed Less Anti-Atherogenic Activity
por: Yoo, Jeong-Ah, et al.
Publicado: (2015)

The unsolved mystery of apoA-I recycling in adipocyte
por: Wang, Shuai, et al.
Publicado: (2016)

Brain ApoA-I, ApoJ and ApoE Immunodetection in Cerebral Amyloid Angiopathy
por: Camacho, Jessica, et al.
Publicado: (2019)

Discoidal HDL and apoA-I-derived peptides improve glucose uptake in skeletal muscle
por: Dalla-Riva, Jonathan, et al.
Publicado: (2013)

PPAR-α Agonist Fenofibrate Reduces Insulin Resistance in Impaired Glucose Tolerance Patients with Hypertriglyceridemia: A Cross-Sectional Study
por: Feng, Xiaomeng, et al.
Publicado: (2017)

Apolipoprotein A-I (ApoA-I), Immunity, Inflammation and Cancer
por: Georgila, Konstantina, et al.
Publicado: (2019)

Serum Levels of ApoA1 and ApoA2 Are Associated with Cognitive Status in Older Men
por: Ma, Cheng, et al.
Publicado: (2015)

Autophagy Alteration in ApoA-I Related Systemic Amyloidosis
por: Del Giudice, Rita, et al.
Publicado: (2022)

ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer
por: Cedó, Lídia, et al.
Publicado: (2016)

Effects of Individual Amino Acids on PPARα Transactivation, mTORC1 Activation, ApoA-I Transcription and pro-ApoA-I Secretion
por: Tayyeb, Jehad Z., et al.
Publicado: (2022)

ApoA-1 improves glucose tolerance by increasing glucose uptake into heart and skeletal muscle independently of AMPKα(2)
por: Fritzen, Andreas Mæchel, et al.
Publicado: (2020)

Human apoA-I[Lys107del] mutation affects lipid surface behavior of apoA-I and its ability to form large nascent HDL
por: Gorshkova, Irina N., et al.
Publicado: (2022)

Elevated ApoB/ApoA-I ratio is associated with acute anti-N-Methyl-D-aspartate receptor encephalitis, but not disease outcomes
por: Liu, Yingying, et al.
Publicado: (2022)

Effect of apoA-I on cholesterol release and apoE secretion in human mature adipocytes
por: Bencharif, Karima, et al.
Publicado: (2010)

HDL-apoA-I Exchange: Rapid Detection and Association with Atherosclerosis
por: Borja, Mark S., et al.
Publicado: (2013)

SIDT2 Associates with Apolipoprotein A1 (ApoA1) and Facilitates ApoA1 Secretion in Hepatocytes
por: Sampieri, Alicia, et al.
Publicado: (2023)

ApoA-1 in Diabetes: Damaged Goods
por: Ory, Daniel S., et al.
Publicado: (2010)

Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis
por: Valanti, Eftaxia-Konstantina, et al.
Publicado: (2018)

ApoA-IV improves insulin sensitivity and glucose uptake in mouse adipocytes via PI3K-Akt Signaling
por: Li, Xiaoming, et al.
Publicado: (2017)

ApoA-I-Mediated Lipoprotein Remodeling Monitored with a Fluorescent Phospholipid
por: Neufeld, Edward B., et al.
Publicado: (2019)

Association of serum apoA-I with in-stent restenosis in coronary heart disease
por: Wang, Xin, et al.
Publicado: (2022)

High ApoB/ApoA-I Ratio Predicts Post-Stroke Cognitive Impairment in Acute Ischemic Stroke Patients with Large Artery Atherosclerosis
por: Lee, Minwoo, et al.
Publicado: (2023)

Iowa Mutant Apolipoprotein A-I (ApoA-I(Iowa)) Fibrils Target Lysosomes
por: Kameyama, Hirokazu, et al.
Publicado: (2016)

The effects of cranberry juice on serum glucose, apoB, apoA-I, Lp(a), and Paraoxonase-1 activity in type 2 diabetic male patients
por: Shidfar, Farzad, et al.
Publicado: (2012)

RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist
por: McLure, Kevin G., et al.
Publicado: (2013)

Effect of apoA-I PEGylation on the Biological Fate of Biomimetic High-Density Lipoproteins
por: Pedersbæk, Dennis, et al.
Publicado: (2020)

ApoA-I mimetics reduce systemic and gut inflammation in chronic treated HIV
por: Daskou, Maria, et al.
Publicado: (2022)

ApoA-I/A-II-HDL positively associates with apoB-lipoproteins as a potential atherogenic indicator
por: Kido, Toshimi, et al.
Publicado: (2017)

Association of oxidized ApoB and oxidized ApoA-I with high-risk coronary plaque features in cardiovascular disease
por: Sorokin, Alexander V., et al.
Publicado: (2023)

Human Serum Amyloid a Impaired Structural Stability of High-Density Lipoproteins (HDL) and Apolipoprotein (Apo) A-I and Exacerbated Glycation Susceptibility of ApoA-I and HDL
por: Cho, Kyung-Hyun
Publicado: (2022)

LCAT, ApoD, and ApoA1 Expression and Review of Cholesterol Deposition in the Cornea
por: Flores, Rhonda, et al.
Publicado: (2019)

Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio—Experience from the Swedish AMORIS cohort: A cohort study
por: Walldius, Göran, et al.
Publicado: (2021)

Caveolin-1 reduces HIV-1 infectivity by restoration of HIV Nef mediated impairment of cholesterol efflux by apoA-I
por: Lin, Shanshan, et al.
Publicado: (2012)

APOA1-75 G to A Substitution Associated with Severe Forms of CAD, Lower Levels of HDL and apoA-I among Northern Indians
por: Chhabra, S., et al.
Publicado: (2005)

Myriocin-mediated up-regulation of hepatocyte apoA-I synthesis is associated with ERK inhibition
por: Glaros, Elias N., et al.
Publicado: (2010)

Exogenous Expression of Human apoA-I Enhances Cardiac Differentiation of Pluripotent Stem Cells
por: Ng, Kwong-Man, et al.
Publicado: (2011)

Insights into the fate of the N-terminal amyloidogenic polypeptide of ApoA-I in cultured target cells
por: Arciello, Angela, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_nfv1r4b7k9qcniu2a5n0uk6gk5